Metropark Entertainment Hub With Dave & Buster's And More Sets February 2019 Opening Date

Sam Moon Group's Metropark Square
Courtesy of Sam Moon Group
Sam Moon Group's Metropark Square

Dave & Buster's, the popular Dallas-based entertainment food and beverage venue, is opening a new location at Metropark Square near The Woodlands. The entertainment destination is scheduled to open in February 2019. Dave & Buster’s will occupy approximately 40K SF of the 175K SF entertainment and dining destination just north of The Woodlands along Interstate 45.

The Retail Connection's David Fazio, Steve Lieberman and Jonathan Probst, along with MetroCommercial's Steve Niggeman, represented Dave & Buster's. The Retail Connection's Steve Greenberg represented the landlord. Dave & Buster’s will be joining a 41K SF, 10-screen AMC Theatre with IMAX. When complete, the development will feature restaurants, retail, entertainment venues, hotels and multifamily housing, wrapped around a central green space area that will include a pavilion, a fountain and outdoor event space.

Continue reading this story with a free account

Log in or register
Sign up for more articles like this
Subscribe to Bisnow's Houston Newsletters
Related Stories

Cross Ocean Partners, Fuller Realty Acquire 829K SF Houston Office Campus

Trammell Crow Starts Phase Of 2M SF Industrial Park: The Houston Deal Sheet

Oncology Company Expands Footprint At Hines' Life Sciences Campus

Astrodome Conservancy Solicits Redevelopment Ideas

Food And Beverage Increasingly Becoming Anchor In Mixed-Use Projects

Sugar Land Town Square Secures Fortune 500 Lease: The Houston Deal Sheet

Houston CRE Firms Turn To Contractors As They Look To Scale

The Revitalization Of Sugar Creek On The Lake, A Premier Waterfront Property In Greater Houston

City Block Sold For New Houston Center Parking Garage

Beacon Partners Sells Charlotte Mixed-Use Development For $92M

Texas Pauses Data Center Power Connections, Which Could Speed Up Rapid Development

Houston's Generation Park Lands Another $2.3B Pharma Manufacturing Investment